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Therapeutic drug monitoring of atypical antipsychotic drugs
Schizophrenia is a severe psychiatric disorder often associ-
ated with cognitive impairment and affective, mainly de-
pressive, symptoms. Antipsychotic medication is the pri-
mary intervention for stabilization of acute psychotic 
epi sodes and prevention of recurrences and relapses in pa-
tients with schizophrenia. Typical antipsychotics, the older 
class of antipsychotic agents, are currently used much less 
frequently than newer atypical antipsychotics. Therapeutic 
drug monitoring (TDM) of antipsychotic drugs is the spe-
cific method of clinical pharmacology, which involves mea-
surement of drug serum concentrations followed by inter-
pretation and good cooperation with the clinician. TDM is 
a powerful tool that allows tailor-made treatment for the 
specific needs of individual patients. It can help in monitor-
ing adherence, dose adjustment, minimizing the risk of 
toxicity and in cost-effectiveness in the treatment of psychi-
atric disorders. The review provides complex knowledge 
indispensable to clinical pharmacologists, pharmacists and 
clinicians for interpretation of TDM results.    




Therapeutic drug monitoring (TDM) of antipsychotic drugs is the specific method of 
clinical pharmacology for the monitoring of therapy by using measurement of drug serum 
concentrations followed by interpretation and good cooperation with the clinician (1–3). 
Phenotyping and genotyping can raise therapeutic drug monitoring to a higher level. 
Optimal outcomes of TDM require appropriate use of available analytical methods and 
basic knowledge, which must be amalgamated with the clinical situation of the patient, a 
complex joint effort of laboratory specialists, pharmacologists, pharmacists, treating physi-
cians and the patient (4). Antipsychotic medication is the primary intervention for stabili-
zation of acute psychotic episodes and prevention of recurrences and relapses in patients 
with schizophrenia (5). There are two groups of antipsychotic drugs. The older class of 
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perphenazine (6). Currently, these medications are used much less frequently than newer 
atypical antipsychotics. They have fallen somewhat out of favor because of side effects 
(extrapyramidal symptoms, tardive dyskinesia, neuroleptic malignant syndrome).
Atypical antipsychotics
Newer or atypical or second generation antipsychotics include clozapine, risperidone, 
olanzapine, quetiapine, sertindole, ziprasidone, aripiprazole and amisulpride (6). These 
agents tend to be characterized by a low propensity to produce acute extrapyramidal 
symptoms and tardive dyskinesia, a weak potential to cause elevation of serum prolactin 
levels, and a broad spectrum of activity involving not only positive and negative symp-
toms, but also other symptom dimensions of schizophrenia (i.e., cognitive, aggressive and 
depressive symptoms). On the other hand, treatment with some of these medications has 
been associated with a substantial risk of metabolic effects (such as weight gain, hypergly-
caemia and lipid dysregulation), cerebrovascular adverse events (stroke, in particular), and 
cardiovascular adverse events (particularly prolongation of heart-rate corrected QT inter-
val of the electrocardiogram) (7–9). Metabolic side effects seem to be greatest with clozap-
ine and olanazapine, intermediate with resperidon/paliperidon and quetiapine, and rela-
tively minimal with ziprasidone and aripiprazole (10). 
This review provides complex knowledge indispensable to clinical pharmacologists, 
pharmacists and clinicians for interpretation of TDM results.    
Therapeutic drug monitoring
Wanted and unwanted drug effects depend on concentrations of the drug at its target 
site (11). After a given dose, the resulting blood concentrations of antipsychotic drugs are 
higly variable among individuals. The resulting plasma concentration at a given dose can-
not be predicted by the dose. This is certainly a result of interindividual variabilities in 
drug metabolism by hepatic and extrahepatic enzymes. However, other factors, such as 
drug transporters involved in absorption, distribution and elimination, are probably also 
relevant. The patients‘ adherence to taking the drug at the prescribed dose and at recom-
mended times is another factor that contributes to the highly variable blood concentra-
tions. Antipsychotic drugs exert most therapeutic actions by blocking the dopamine D2-
like receptors. It has been shown that plasma concentrations of antipsychotic drugs 
correlate well with receptor occupancy. In accordance with the high variability of drug 
concentrations in plasma under the same doses, it was found that receptor occupancy cor-
relates better with plasma concentrations than with daily doses. Optimal response was 
seen at 70–80 % receptor occupancy, and 80 % receptor occupancy was defined as the 
threshold for the occurrence of extrapyramidal side effects (12, 13).  Therefore, the antipsy-
chotic drug plasma concentration is a valid measure of the drug at its primary target 
structure in the brain (11). Therapeutic drug monitoring of atypical antipsychotics affords 
the opportunity to reduce toxicity and increase adherence (14). However, the clinical value 
of using plasma concentrations of antipsychotics to monitor patients with schizophrenia 
is a contentious issue. Excessively high concentrations may be associated with clinical 
deterioration of the patient because of antipsychotic toxicity. The rationale for using thera-
peutic drug monitoring of atypical antipsychotics is still a matter of debate, but there is 
growing evidence that it can improve efficacy, especially when patients do not respond to 
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therapeutic doses or when they develop adverse effects (15). Monitoring of plasma concen-
trations has contributed to our understanding of cases of non-response to pharmacological 
therapy by distinguishing ‚pseudo‘ drug resistance (characterized by low plasma concen-
trations as a result of greater metabolic activity or poor adherence) and ‚true‘ drug resis-
tance (characterized by appropriate plasma concentrations for the administered dose but 
poor receptor sensitivity). The importance of TDM remains when it comes to identifying 
‚pseudo-pharmacoresistance‘ problems such as poor adherence, high individual levels of 
metabolism, excessive water consumption by patients, excessive smoking, drug abuse, and 
appearance of unpredictable adverse effects and possible drug interactions. 
At usual clinical doses, atypical antipsychotics generally appear not to markedly af-
fect the metabolism of co-administered medications (16, 17). However, these agents are 
subject to drug-drug interactions with other psychotropic agents or with medications used 
in the treatment of concomitant physical illnesses. Most pharmacokinetic interactions with 
newer antipsychotics occur at the metabolic level and usually involve changes in the activity 
of major drug-metabolizing enzymes involved in their biotransformation, i.e., the cyto-
chrome P450 (CYP) monooxygenases and/or uridine diphosphate-glucuronosyltransfer-
ases (UGT). Most documented metabolic interactions involve antidepressant and anti epi-
leptic drugs (Table I). Tobacco smoking is associated with induction of drug metabolizing 
enzymes, namely, CYP1A2 and, possibly, UGTs. Smoking may influence elimination of 
antipsychotics, such as clozapine and olanzapine, whose metabolism is mainly dependent 
on CYP1A2 and UGTs. 
Table I.  Effect of various selective serotonin reuptake inhibitors (SSRIs) and antiepileptics on plasma 
concentrations of antipsychoticsa
Antipsychotic SSRI Effect on plasma level Antiepileptic Effect on plasma level
Clozapine Fluoxetine Increase (40–70 %) Carbamazepine Decrease (50 %)
Paroxetin Increase (20–40 %) Valproic acid No change/minimal increase
Fuvoxamine Increase (up to 5–10 times) Phenobarbital Decrease (30–40 %)
Risperidone Fluoxetine Increase (75 %) Carbamazepine Decrease (50–70 %)
Paroxetine Increase (40–50 %)
Fluvoxamine Minimal increase (10–20 %)
Sertraline Minimal increase
Olanzapine Fluoxetine No change/minimal increase Carbamazepine Decrease (30–70 %)
Fluvoxamine Increase (up to 100%) Lamotrigine No change/minimal increase
Quetiapine Carbamazepine Decrease (80 %)
Valproic acid Increase (70–80 %)
Phenytoin Decrease (80 %)
Aripiprazole Valproic acid Decrease (20–30 %)
Ziprasidone Carbamazepine Decrease (20–40 %)
a Only data from controlled studies are used (14).
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Determination of psychotropic drugs
Various methods are used for the determination of drugs in biological fluids: imu-
nonochemical, electromigration or electrophoretic and chromatographic methods, which 
provide high detection sensitivity and determination of drugs and their active and non-
active metabolites in one run (18). Immunochemical methods, in comparison with chro-
matographic methods, do not allow determination of a single drug and its metabolites. 
Another disadvantage is the cross-reaction in which antibodies react differently with dif-
ferent metabolites, which hinders accurate quantification. The risk of interferences increas-
es with structural similarities (19). In 1979, Brunswick et al. (20) described a specific radio-
immunoassay for the determination of amitriptyline and nortriptyline. As the 
immunochemical methods have a relatively high limit of detection, they are preferably 
used as a screening of overdose rather than for therapeutic drug monitoring. Chromato-
graphic methods, which have been most commonly used in recent years, include high 
performance liquid chromatography (HPLC) and gas chromatography (GC). Gas chroma-
tography is used for the determination of antidepressant drugs, since many of them are 
structured amines. GC is a simple, high-resolution, sensitive, reproducible and inexpen-
sive method. Fernandes et al. (21) published a method for the determination of fluoxetine 
in plasma by gas chromatography with mass spectrometric detection (GC-MS). Eap et al. 
(22) published a GC-MS method for the determination of citalopram, paroxetine, sertraline 
and their metabolites in plasma after derivatization. We have developed an LC-MS method 
for determination of five antidepressants and four atypical antipsychotics and their main 
metabolites in human serum (23). The method can be used for phenotyping, since it en-
ables simultaneous measurement of parent drugs and the main metabolites. Kirchherr and 
Kühn-Velten (24) published a method for determination of forty-eight antidepressants and 
antipsychotics in human serum by HPLC-tandem mass spectrometry. Among the advan-
tages of HPLC-MS is its wide range of applications, and the possibility to identify different 
combinations of active ingredients together with their active metabolites.
TDM of particular atypical antipsychotic drugs
Clozapine. – After oral administration, the drug is rapidly absorbed. Only 27–50 % of 
the dose reaches the systemic circulation unchanged because of extensive first-pass me-
tabolism (25–28). It is 95 % bound to plasma proteins, primarily alpha-1-acid glycoprotein. 
The maximum plasma concentration (cmax) is reached within 1–4 hours after dosing. The 
mean half-life ranges from 9 to 17 hours. Steady-state plasma concentrations are reached 
after 7–10 days of dosing. Clozapine is primarily metabolized by CYP1A2, with additional 
contributions of CYP2C19, CYP2D6 and CYP3A4. Glucuronidation by UGT1A1, 1A3 and 
1A4 is an important pathway in clozapine metabolism. The main active metabolites of 
clozapine are norclozapine (CYP1A2) and clozapine-N-oxide (CYP3A4), which are found 
in plasma concentrations that are usually 50–90 and 10–35 %, respectively, of clozapine 
concentrations  (15). It has also been reported that clozapine and clozapine-N-oxide can 
interconvert, and this reversible metabolic pathway could at least partly explain the vari-
ability of plasma clozapine  concentration among patients. Plasma clozapine concentra-
tions vary widely between individuals, so the oral dose is not a reliable indicator of plasma 
drug concentrations (29). This wide variability is a result of interindividual differences in 
bioavailability and the fact that clozapine is metabolized by the highly variable activity of 
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CYPlA2. However, serum determinations showed an acceptably low mean intrapatient 
variability of 20 %, which means that serum clozapine determinations can be used to as-
sess patient adherence. The high interindividual and low intraindividual variability of 
plasma clozapine concentrations confirm the usefulness of TDM. Both the antipsychotic 
efficacy and the adverse effects of clozapine are positively correlated with the plasma con-
centration of the drug. Norclozapine is not a useful predictor of therapeutic response (30). 
Most researchers have found that the threshold plasma clozapine concentration at steady-
state of 350–420 ng mL–1 is associated with increased probability of a good clinical re-
sponse to the drug (15). Furthermore, in a follow-up study of a sample, the concentration- 
-response relationship was found to be consistent over a 2.5-year period. In addition, five 
of seven previous non-responders became responders when plasma clozapine concentra-
tions were increased to above 350 ng mL–1. There is also a relationship between serum 
clozapine concentrations and CNS adverse effects. For example, Olesen et al. (31) found a 
significant correlation between clozapine concentrations and EEG changes. Concentra-
tions above 1000 ng mL–1 significantly increased the risk of confusion, delirium and ge-
neralized seizures (31, 32). Clozapine-induced obsessive/compulsive symptoms have been 
reported by many authors as not uncommon side effects. The authors suggest that the 
emergence of these side effects may be related to higher plasma concentration of clozapine 
and clinicians should routinely check for and manage these side effects (33). Inflammatory 
reactions may suddenly increase clozapine concentrations and lead to toxic delirium (34). 
Plasma clozapine concentrations (and the probability of reaching a given threshold) may 
be influenced by some factors, such as age, sex and smoking (15). Because of the degree of 
interindividual variability of the clozapine concentration-to-dose ratio, dosages of 900 to 
1800 mg day–1 are necessary in 15 % of patients to obtain clozapine concentrations of ≥ 400 
ng mL–1. These patients are most likely to be males who smoke cigarettes. Thus, patients 
requiring these higher dosages should probably be titrated more cautiously to avoid the 
adverse effects associated with higher dosages, such as seizures and confusion (14). 
Changes in the habitual caffeine intake alter the metabolism of clozapine in schizophrenic 
patients (35). Thus, a patient‘s intake of caffeine should be medically supervized and the 
monitoring of clozapine and metabolite levels may be warranted. Interindividual vari-
ability in CYP1A2 activity may potentially explain treatment resistance to clozapine in 
some patients (36). CYP1A2 phenotyping with a simple caffeine test may contribute to 
individualization of clozapine dosage and differentiation between treatment non-adher-
ence and high CYP1A2 activity. TDM can potentially decrease the lag time to response by 
administering dosages to patients that produce a therapeutic clozapine concentration in 
plasma (14). Empirically determined regimens may require months to optimize clozapine 
treatment in patients with schizophrenia. Logically, however, TDM should shorten the 
patient response time, since patients with lower plasma clozapine concentrations consis-
tently have significantly lower response rates and will eventually be titrated to higher 
dosages and plasma drug concentrations. Reduction of relapse rates by TDM is highly 
cost-effective, as relapses can lead to hospitalization (37). It has been shown that fluctua-
tions of clozapine plasma concentrations in schizophrenic patients are predictive of re-
lapses and rehospitalizations. In these patients, TDM may help reduce the risk of relapse 
or recurrence by increasing medication adherence. One day in the hospital is 4–16 times 
more expensive than a single drug concentration measurement in the laboratory. Clozap-
ine still represents the gold standard in the treatment of pharmacoresistant schizophrenia 
and optimal plasma levels for acute and maintenance clozapine treatment are well known 
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(38). Literature experiences show that TDM in clinically defined patient subgroups such as 
pharmacoresistant schizophrenia is clinically advantageous.
Risperidone. – It is rapidly absorbed after oral administration, with the cmax reached in 
approximately 1 hour (15). Its oral bioavailability is 70–85 %. Risperidone is 89 % bound to 
plasma proteins. It mainly undergoes 9-hydroxylation in the liver, which yields the active 
9-hydroxyrisperidone (9-OH-RSP – paliperidone) metabolite, a step that is mainly cata-
lyzed by CYP2D6 and, to a lesser extent, by CYP3A4. Alicyclic dehydroxylation and oxida-
tive N-dealkylation are minor metabolic pathways. Genetic influences, such as the  CYP2D6 
status, play an important role in determining the variability of its pharmacokinetic param-
eters. The mean elimination half-life of risperidone is 3 hours in extensive metabolizers 
and 22 hours in poor metabolizers. Steady-state concentrations are reached within 4–6 
days of treatment. The mean elimination half-life of the active moiety (risperidone + its 
main metabolite) is almost constant at about 22 hours in both groups. There are large intra- 
and inter-individual variations in plasma concentrations of both risperidone and 9-OH-
RSP. As the pharmacological properties of 9-OH-RSP are similar to those of risperidone, 
both are regarded as being able to contribute to the drug‘s overall antipsychotic effects in 
the treatment of schizophrenia, and thus represent the active moiety. The overall pharma-
cological effects of risperidone depend on the sum of plasma concentrations of risperidone 
and its 9-OH-RSP metabolite (total active moiety), so monitoring plasma concentrations of 
the parent compound (risperidone) alone can lead to erroneous interpretations. Therapeu-
tic drug monitoring of risperidone may be beneficial in certain circumstances, including 
assessing potential non-adherence and supporting adherence, ruling out therapeutic fail-
ure as a result of low drug concentrations, and identifying and managing drug interac-
tions, adverse effects, and use in special populations (39). Moreover, risperidone TDM 
should be particularly useful when medication is switched from the oral to injectable de-
pot form or vice versa (15). In chronic schizophrenic patients experiencing an acute exa-
cerbation of the disorder, plasma levels of risperidone and its active metabolite correlate 
with the occurrence of parkinsonian side effects (40). Risperidone plasma concentration/
dose ratio (C/D) accumulation peaks of 49 % at 2 months (from baseline concentration) and 
9-hydroxy-risperidone and total moiety C/D accumulation peaks of 66 and 55 % above the 
2-month level at 6 months were found (41). Risperidone conversion to 9-hydroxy-risperi-
done by CYP2D6 suggests CYP2D6 inhibition or DNA down-regulation in the first 2 
months. The time course of the accumulations identified suggests that both CYP inhibition 
and DNA regulatory mechanisms may be involved in the metabolism of the drug. There-
fore, long-term TDM can optimize treatment with risperidone.
Paliperidone. – The 9-hydroxyrisperidone is now marketed as an antipsychotic in its 
own right (15, 42, 43). The absolute oral bioavailability of paliperidone is 28 %. It is 74 % 
protein bound, primarily to albumin and α1-acid glycoprotein. Peak plasma concentra-
tions are reached approximately 24 hours after dosing. Paliperidone undergoes a very 
limited hepatic metabolism, with approximately 60 % of unchanged drug eliminated re-
nally and 11 % eliminated unchanged in the feces. The terminal half-life of paliperidone 
is about 23 hours with the steady state concentration attained in 4–5 days.
Olanzapine. – Approximately 85 % of an oral olanzapine dose is absorbed, but as 40 % 
is inactivated by first-pass hepatic metabolism, its oral bioavailability is 60 % (15). The cmax 
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is reached within 6 hours. The drug is 93 % bound to plasma proteins, mainly albumin 
(90 %) and alpha1-acid glycoprotein (77 %). It has a mean elimination half-life of 33 hours 
(range 21–54 hours) and steady-state concentrations are achieved within 5–7 days of ad-
ministration. Olanzapine is metabolized primarily by direct glucuronidation and CYP1A2 
and to a lesser extent by CYP2D6, CYP3A4 and flavin monooxygenase to its 10-N- and 
4‘-N-glucuronides, 4‘-N-desmethylolanzapine, olanzapine-N-oxide, and 2-hydroxymethyl-
olanzapine. The 10-N-glucuronide is the most abundant metabolite. Glucuronidation by 
the UDP-glucuronosyltransferase family of enzymes (1A4 and 2B10) is the major mode of 
olanzapine metabolism, and polymorphisms in these enzymes could contribute to inter-
individual variability in olanzapine metabolism and therapeutic response (44). Studies 
have shown that mean plasma olanzapine concentrations vary widely, depending on fac-
tors such as the prescribed daily dose and the duration of treatment (41). Olanzapine 
showed a plasma concentration/dose ratio accumulation peak after 4 months of 31 % above 
baseline, and a slower increase to 47 % above baseline after 18 months with no clear pla-
teau. The time course of the accumulations identified suggests that both CYP inhibition 
and DNA regulatory mechanisms may be involved in the metabolism of the drug. There-
fore, long-term TDM can optimize treatment with both risperidone and olanzapine, and 
also antipsychotics in general. Smokers and men show greater olanzapine clearance than 
women and nonsmokers (15). Given their lower olanzapine clearance, women have sig-
nificantly higher mean plasma olanzapine concentrations, which become evident after the 
fifth week of treatment. Studies strongly indicate a relationship between clinical outcomes 
and plasma olanzapine concentrations. A therapeutic range at steady-state between 20 and 
80 ng mL–1 has been found (37). The positron emission tomography (PET) data available 
for olanzapine indicate that a threshold level of approximately 15–20 ng mL–1 should be 
targeted in order to get an antipsychotic response in the average patient with schizophre-
nia (45). Levels above 50 ng mL–1  might be associated with a higher risk of extrapyramidal 
symptoms. Furthermore, given the large interpatient variability in plasma olanzapine con-
centrations at the same dosages, olanzapine TDM can be considered very useful in assess-
ing therapeutic efficacy and controlling adverse events (15). Stopping smoking may be 
associated, within a few days, with an increase in side effects, such as extrapyramidal 
symptoms, unless the dose is adjusted. 
Quetiapine. – It is rapidly absorbed following oral administration and 70 % of the ad-
ministered dose is absorbed (15). Median cmax is reached within 1–1.5 hours, the drug is 
83 % bound to plasma proteins and is eliminated with an elimination half-life of 5–8 hours. 
Steady-state concentrations are achieved within 2–3 days of administration. The primary 
route of elimination is hepatic metabolism. Quetiapine is predominantly metabolized by 
CYP3A4, which is the main iso-enzyme involved in quetiapine sulfoxidation and dealkyl-
ation, and by CYP2D6 which is involved in the 7-hydroxylation of quetiapine (along with 
CYP3A4). Of the 11 metabolites formed as a result of the hepatic metabolism of quetiapine, 
only two (7-hydroxy-quetiapine and 7-hydroxy-N-desalkyl-quetiapine) are pharmacologi-
cally active and they circulate in plasma at rather low concentrations (12 % of those of 
quetiapine). If this is the case, it is unlikely that they contribute to the pharmacological 
effects of the drug. Oral clearance of quetiapine seems to be lower (30–50 %) in elderly 
patients (aged 63–85 years) receiving 300–750 mg per day than in younger patients on 
similar regimens. It should be noted that the age of > 70 years has been found to be associ-
ated with a marked decline in the hepatic content of CYP3A4. Dose titration may therefore 
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need to be slower in the elderly, and the daily dose lower than in younger patients (15). 
Although the data from Gefvert et al. (46) and Mauri et al. (47) argue in favour of the exis-
tence of a relationship between plasma quetiapine concentrations and clinical responses, 
they only provide some preliminary information about the meaning of plasma quetiapine 
concentrations. Other investigators have failed to identify an optimal therapeutic range for 
quetiapine (48, 49). Data from the available PET studies provide evidence for a therapeutic 
reference range at a steady-state of 100–500 ng mL–1. Higher plasma concentrations might 
be tolerable to many patients, and their tolerability is limited by vegetative side effects and 
sedation rather than extrapyramidal symptoms (45). 
Amisulpride. – It is rapidly absorbed after oral administration, its absolute bioavail-
ability is about 50 % and cmax is reached after 1–4 hours (15). Amisulpride has low protein 
binding (17 %), its elimination half-life is 12–20 hours and the steady state is reached after 
2–3 days. It undergoes minimal metabolism in the liver and produces only two main me-
tabolites, both of which are inactive. Excretion occurs mainly via kidneys, by glomerular 
filtration and it is therefore likely that active drug secretion occurs. In patients with renal 
impairment, its elimination half-life is unchanged, but systemic clearance is reduced by 
one-third, so dose adjustments are required. Age and sex have a significant effect on dose 
corrected amisulpride plasma concentrations, which are higher in older patients and in 
women, possibly because of a sex difference in the drug‘s renal clearance. Co-medication 
with lithium and clozapine increases dose-corrected amisulpride plasma concentrations. 
Like in the case of most antipsychotics, patients commonly show great interindividual 
variance in plasma amisulpride concentrations. Amisulpride plasma concentration is 
closely correlated with the dose, dopamine occupancy, response and extra-pyramidal 
symptoms (EPS). The plasma concentration threshold for response appears to be approxi-
mately 200 ng mL–1 at steady-state and EPS are more reliably predicted by a plasma level 
above 320 ng mL–1  than by the dose (50). TDM of amisulpride seems to be very useful for 
clinical decision making (51).
Ziprasidone. – Its oral bioavailability is 60 % but the duration and extent of ziprasidone 
absorption may be as much as doubled in the presence of food, whereas its elimination 
half-life is shorter than under fasting conditions (15, 17). Ziprasidone is highly bound to 
plasma proteins (> 99 %), primarily albumin and alpha-1-acid glycoprotein. Its pharmaco-
kinetics seem to be linear, the elimination half-life has been reported to be 8–10 hours. 
Steady-state concentrations are achieved within 2–3 days of administration. Ziprasidone 
is highly metabolized by CYP3A4 and aldehyde oxidase, with < 5 % of the administered 
dose being excreted in an unchanged form. Clinical improvement or side effects did not 
correlate significantly with doses or serum levels. However, great interindividual and in-
traindividual differences in ziprasidone concentrations were observed. TDM of ziprasi-
done may be used for individual dose adjustments and monitoring of medication adher-
ence (52, 53). The available PET studies with ziprasidone suggest that an antipsychotic 
effect can be expected above a threshold level at steady-state of approximately 50 ng mL–1. 
Levels above 200–250 ng mL–1 might be associated with a higher incidence of extrapyrami-
dal symptoms (45).
Aripiprazole. – It is well absorbed, its oral bioavailability is 87 % and cmax is reached 
after 3–5 hours of administration (15). It is extensively bound to plasma proteins (> 99 %), 
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primarily to albumin. The elimination half-life is 47–68 hours, steady-state plasma concen-
trations being reached by day 14. A linear pharmacokinetic profile has been observed. 
Aripiprazole is metabolized in the liver via CYP3A4 and CYP2D6, primarily as a result of 
dehydrogenation, hydroxylation and N-dealkylation. At steady state, 40 % of the plasma 
aripiprazole concentration is represented by the major active metabolite dehydro-aripip-
razole.
The dose range for aripiprazole is well defined, and it reliably predicts the plasma 
level, dopamine receptor occupancy, and clinical response (54). Plasma level variation ap-
pears to have a minimal impact on clinical response, but it may predict some adverse ef-
fects. Therapeutic drug monitoring has a limited value in the clinical use of aripiprazole, 
but it may be useful in assuring adherence and optimizing the response in individuals.
Sertindole. – It is well absorbed when administered orally; its bioavailability is 75 %. It 
is 99.5 % bound to plasma proteins, cmax is reached after 8–12 hours (15). The mean elimina-
tion half-life is 85–99 hours and steady state is achieved after 15–20 days. The results of in 
vivo experiments suggest that the metabolism of sertindole is principally mediated by 
CYP3A4 and CYP2D6 and the known variability of these two iso-enzymes probably con-
tributes to the observed variability in the pharmacokinetics of sertindole. It is metabolized 
to two compounds, dehydro-sertindole (active) and nor-sertindole. Care is needed when 
calculating effective doses in patients with hepatic insufficiency. It would be useful to fol-
low plasma sertindole concentrations in case of an overdose, because of its long elimina-
tion half-life (3–5 days) and capacity to prolong the QT interval. Concentration dependent 
increase of QT interval by blockade of potassium chanels has been also reported (37). Basic 
characteristics and enzymes involved in the metabolism of atypical antipsychotic drugs 
are presented in Tables II and III.
Guidelines for optimal use of TDM in psychiatry
The TDM group of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmako-
psychiatrie (AGNP) has published literature-based guidelines for optimal use of TDM in 
psychiatry and defined 4 levels of recommendations, based on empirical evidence: level 
1 – strongly recommended, level 2 – recommended, level 3 – useful, and level 4 – poten-
tially useful (Table IV) (37). The so called laboratory alert levels indicate drug concentra-
tions above the recommended reference range that cause the laboratory to feedback im-
mediately to the prescribing physician. The laboratory alert should lead to dose reduction 
when the patient exhibits signs of intolerance or toxicity. When the high drug concentra-
tion is well tolerated by the patient and if dose reduction bears the risk of symptom exac-
erbation, the dose should remain unchanged. For a number of psychoactive drugs, me-
tabolites actively contribute to the overall clinical effect of the parent compound. For this 
reason, TDM must include the quantification of active metabolites, e.g., in the case of ris-
peridone. Analysis of pharmacologically inactive metabolites, however, may give useful 
information on the metabolic state of the patient or on his/her adherence. Table V shows 
the normal ratios of concentrations of metabolites to parent drugs. Calculated ranges con-
tain 68 % of the ratios expected under standard dosages, i.e., ratios within the range of the 
mean ± 1 SD assuming normal distribution. A ratio above or below the normal ratio  can 
indicate problems of drug adherence or metabolic abnormalities due to a genetic variation 
or a drug-drug interaction with co-medications exhibiting enzyme inhibiting or inducing 
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Time to reach 
steady state (d)
Amisulpride 50 17 1–4 12–20 2–3
Aripiprazole 87 > 99 3–5 47–68 14
Clozapine 27–50 95 1–4 9–17 7–10
Olanzapine 60 93 6 21–54 5–10
Paliperidone 28 74 24 23 4–5
Quetiapine 70 83 1–1,5 5–8 2–3
Risperidone 70–85 89 1 EM: 3, PM: 22 4–6
Sertindole 75 > 99 8–12 85–99 15–20
Ziprasidone 60 > 99 6–8 8–10 2–3
EM – extensive metabolizer, PM – poor metabolizer, tmax – time to reach maximum plasma concentration
Table III.   Enzymes involved in the metabolism of antipsychotic drugs  (12, 14, 38)
Drug Enzymes responsible for metabolization Active metabolite
Amisulpride Excretion via the kidney
Aripiprazole CYP3A4, CYP2D6 Dehydroaripiprazole
Clozapine CYP: 1A2, 2C19, 3A4, 2D6  UGT: 1A1, 1A3, 1A4 Norclozapine, Clozapine-N-oxide
Olanzapine
CYP: 1A2, 2D6, 3A4 
UGT: 1A4, 2B10 
Flavin monooxygenase
Quetiapine CYP3A4, CYP2D6 Norquetiapin
Risperidone CYP2D6, CYP3A4 9-Hydroxyrisperidone
Sertindole CYP3A4, CYP2D6 Dehydrosertindole
Ziprasidone CYP3A4, aldehyde oxidase
CYP – cytochrome P450, UGT – uridine diphosphate-glucuronosyltransferase
properties. In a patient who is genotyped as a poor or ultrarapid metabolizer the medica-
tion should not be automatically replaced by another, but the dose can often be adapted, 
using clinical judgement and TDM. AGNP recommends regular monitoring of plasma 
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Table IV.  Recommended therapeutic reference ranges, laboratory alert levels and levels of recommendation for 
therapeutic drug monitoring (38)
Drug Level Therapeutic reference range (ng mL–1)
Laboratory alert level  
(ng mL–1)
Amisulpride 1 100–320 640
Aripiprazole 2 150–500 1000
Clozapine 1 350–600 1000
Olanzapine 1 20–80 150
Paliperidone (9-hydroxyrisperidone) 2 20–60 120
Quetiapine 2 100–500 1000
Risperidone + 9-hydroxyrisperidone 2 20–60 120
Sertindole 2 50–100 200
Ziprasidone 2 50–200 400
1 – strongly recommended, 2 – recommended
Table V.   Ranges of metabolite-to-parent drug concentration ratios (38)
Drug Metabolite Ratio metabolite concentrations/parent drug [(mean – SD) – (mean + SD)]
Aripiprazole Dehydroaripiprazole 0.3–0.5; PM of CYP2D6: 0.2
Clozapine Norclozapine non smokers: 0.5–0.6; smokers: 0.4–0.7
Olanzapine N-demethylolanzapine non smokers: 0.1–0.3; smokers: 0.2–0.4 
Quetiapine Norquetiapine 0.1–3.8
Risperidone 9-hydroxy-risperidone CYP2D6: EM/IM 1.5–10.0; PM ≤ 1
Risperidone depot 9-hydroxy-risperidone EM: 1.2–4.3
Sertindole Dehydrosertindole 1.1–2.7; PM of CYP2D6: 1.0
EM – extensive metabolizer, IM – intermediate metabolizer, PM – poor metabolizer, CYP – cytochrome P450
concentrations under maintenance therapy, at least every 3–6 months, to prevent relapses 
and rehospitalizations. Frequency of TDM requests may be increased if patients are known 
to be non-adherent to the medication or in case of changes of co-medications or of smoking 
that affect the pharmacokinetics of the drug. As a rule, trough concentrations are mea-
sured, but in some situations peak concentrations would show a better correlation with 
adverse effects. Blood should be collected after at least four drug elimination half-lives 
after the start of or a change in dosage. In clinical practice, the appropriate sampling time 
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for most psychoactive drugs is one week after stable daily dosing and immediately before 
ingestion of the morning dose. TDM of antipsychotics is also useful when medication is 
switched from the oral to the depot form, or vice versa. There is good evidence for the treat-
ment with antipsychotic drugs that clinical non-improvement at week 2 is highly predic-
tive of later response and remission. Especially, the absence of early improvement appears 
to be a highly reliable predictor of later non-response. For dose titration with antipsy-
chotic drugs, it is therefore recommended to include symptom rating by the treating phy-
sician at baseline and at week 2  in addition to TDM. Plasma concentration determinations 
for antipsychotic drugs should be carried out regularly even in patients on stable doses 
over a period of many months (41). Timely plasma concentration determinations of anti-
psychotics could enhance the physicians‘ ability to optimize drug dosage and make dos-
age reductions in a more scientific manner than it is the current standard of practice. 
CONCLUSIONS
In conclusion, TDM of antipsychotic drugs is a powerful tool that allows tailoring the 
treatment to the specific needs of individual patients. It can help in monitoring adherence, 
in dose adjustment, in minimizing the risk of toxicity and in cost-effectiveness in the treat-
ment of psychiatric disorders.
Acronyms, abbreviations, codes. – 9-OH-RSP – 9-hydroxyrisperidone; AGNP – the TDM 
group of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychi-
atrie; C/D – concentration/dose ratio; cmax – maximum plasma concentration; CYP – cyto-
chrome P450; EM – extensive metabolizer; EPS – extra-pyramidal symptom; IM – inter-
mediate metabolizer; PET – positron emission tomography; PM – poor metabolizer; SSRI 
– selective serotonin reuptake inhibitor; TDM – therapeutic drug monitoring; tmax – time to 
reach maximum plasma concentration; UGT – uridine diphosphate-glucuronosyltransfe-
rase
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